American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
 Securities Case - EconoTimes)
NEW YORK, March 09, 2016 -- Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics, Inc. (ESPR). Esperion investors are encouraged to contact Scott + Scott at (866) 326-5057 or email [email protected] to discuss their legal rights.
About the Lawsuit
Esperion is a pharmaceutical company that focuses on developing and commercializing oral low-density lipoprotein cholesterol ("LDL-cholesterol") lowering therapies. The securities lawsuit alleges that Esperion issued a press release on August 17, 2015 about its lead product candidate, ETC-1002, that was false and was in conflict with a September 28, 2015 press release.
On August 17, 2015, Esperion stated that it "remains on track to initiate the ETC-1002 Phase 3 development program by the end of 2015" and that, "[b]ased on feedback from the FDA, approval of ETC-1002 in the HeFH and ASCVD patient populations will not require the completion of a cardiovascular outcomes trial (CVOT)."
On September 28, 2015, Esperion stated that "[f]or patients on maximally tolerated statin therapy who require additional LDL-C lowering, Esperion will plan to conduct efficacy and long-term safety trials. FDA has encouraged the Company to initiate a cardiovascular outcomes trial promptly … since any concern regarding the benefit/risk assessment of ETC-1002 could necessitate a completed cardiovascular outcomes trial before approval."
On this news, shares of the Company's stock declined $16.76 per share, or over 47%, to close on September 29, 2015 at $18.33 per share.
What you can do
If you purchased shares of Esperion stock, you may have legal claims against the Company. If you wish to discuss the investigation, or have questions about your legal rights, please contact Geoffrey M. Johnson, Esq. or Joseph Halloran, Esq. by telephone at (866) 326-5057 or by email at [email protected] or [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott + Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California and Ohio.
CONTACT:
Geoffrey M. Johnson, Esq.
Joseph Halloran, Esq.
(216) 229-6088, toll-free (866) 326-5057
[email protected]
[email protected]
